Provisions for Drug Advertisement Examination
State Food and Drug Administration，State Administration for Industry and Commerceof the People’s Republic of China
Provisions for Drug Advertisement Examination
(SFDA Decree No. 27)
The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.
Shao Mingli
Commissioner
State Food and Drug Administration
Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China
March 13, 2007
Provisions for Drug Advertisement Examination
Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.
Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.
Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.
Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.
Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.
Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.
Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.
An applicant may entrust an agent with the application for a drug advertisement approval number.
Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.
An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.
Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.
The copy of any approval document prescribed in this Article shall be sealed by the document holder.
Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.
Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.
Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.
For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.
The drug regulatory departments shall announce the approved drug advertisement timely.
Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.
Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.
The copy of any document prescribed in this Article shall be sealed by the document holder.
Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.
Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.
Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.
Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.
Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.
Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.
Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.
Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.
(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.
After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.
Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.
Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.
Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.
After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.
Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.
Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.
Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.
Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.
Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.
Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.
Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.
Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.
Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.
In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.
Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.
Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.
Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.
关于下发《全国范围清理拖欠方案实施细则》的通知
中国人民银行
关于下发《全国范围清理拖欠方案实施细则》的通知
银传［1990］32号
中国人民银行各省、自治区、直辖市分行，计划单列城市分行，中国工商银行、中国农业银行、中国人民建设银行、中国银行、交通银行：.
根据国务院办公厅转发的《全国范围清理拖欠实施方案》的规定，总行拟定了《全国范围清理拖欠实施细则》。现发给你们，请立即转知所属，贯彻执行。
一九九○年七月
附件：全国范围清理企业拖欠货款方案实施细则
根据《全国范围清理企业拖欠货款实施方案》有关规定，为统一操作，保证全国清欠工行顺利进行，特制定本实施细则。
一、发出清欠专用托收承付凭证
从1990年8月1日起，至8月15日止，为办理发出清欠专用托收承付凭证的时间，并进行下列操作：
1.收款企业原则上须一次向开户行开列清欠清单及清欠专用托收承付凭证，大型企业工作量较大的，经开户行同意可分次办理。
2.清欠清单列明付款企业和开户行名称、拖欠货款金额和拖欠发生时间，清单格式由各行自定。
3.清欠专用托收承付凭证一律使用现行的电划异地托收承付结算凭证。按付款企业分别填制，同一付款企业并填一笔。企业名称必须填写全称，开户行名应填明某专业银行。凭证应附上原收款凭证的副本、复印件或有关证明材料。
4.收款企业开户行的信贷部门要按照清欠方案第一条的规定，严格审查企业交来的清欠清单及托收凭证，符合规定的，在托收凭证各联加盖“清欠货款”戳记(样式各行自定)后，将凭证送交会计部门办理发出托收，清欠清单留存备查。
5.收款企业开户行的会计部门收到信贷部门送来经审查符合规定的清欠托收凭证后，按托收承付结算核算手续的规定，加盖业务公章，将有关各联凭证及附件寄往付款企业开户银行，并按规定向收款企业收取邮电费和手续费，同时登记“清欠发出托收登记薄”。
二、收到托收与落实承付货款
从1990年8月上旬起，至9月14日以前，为收到清欠专用托收承付凭证和落实承付货款的时间，并进行下列操作：
1.付款企业开户银行的会计部门收到收款企业开户银行寄来的清欠专用托收承付凭证后，登记“清欠定期代收登记薄”，将托收凭证送交信贷部门审查。
2.信贷部门要按照清欠方案第一条的规定，进行认真审查，对符合规定的立即通知付款企业准备付款。
3.付款企业对所欠债务，要按照顾全大局、主动偿还的精神，积极筹措资金，准备付款。根据清欠方案安排资金的顺序，付款企业应通知开户银行同意承付的金额，其中：结算户承付的金额、向财政或企业主管部门落实拨补资金承付的金额、向银行申请贷款承付的金额。
4.付款企业开户银行收到付款企业承付货款资金安排的通知后，应进行审查核实，对要求银行注入资金承付的，如符合信贷政策和条件，可暂作意向性落实。
5.付款企业对拒付的货款，应提出全部或部分拒付理由书，交开户银行审查，如拒付理由不能成立，开户银行应通知其准备付款。经开户银行审查同意的全额拒付，可将拒付理由书连同原托收凭证一起寄回收款企业开户银行转收款企业，收付双方开户银行销记发出、代收登记薄。部分拒付的，留待划出部分承付时，作划款凭证附件。
6.在落实承付货款时限内，付款企业既未通知开户银行落实付款的资金安排，又未提出拒付的，即视为同意付款，清欠付款开始后，由开户银行从结算户中主动扣收。
三、上报清欠数据和下达清欠资金规模
1990年8月30日为省、区、市人民银行上报清欠有关数据时间，9月5日前后为总行下达清欠资金和规模时间，并进行下列操作：
1.凡在人民银行开户的基层专业银行，应将所属行处下列三项数据，汇总统计报开户的人民银行，并同时逐级上报专业银行总行：
(1)发出清欠专用托收凭证金额。根据“清欠发出托收登记薄”累计数统计。
(2)收到清欠专用托收凭证金额。根据“清欠定期代收登记薄”累计数统计。
(3)应承付货款金额。根据付款企业落实承付货款金额汇总统计。
2.人民银行省市及计划单列市分行应于8月30日前上报人民银行总行清欠办公室。
3.人民银行总行汇总全国三项数字后，进行测算、平衡后，将清欠专用资金和贷款规模于9月5日前后下达各省、市和计划单列市分行。
四、办理付款和收款
从1990年9月15日起，至10月10日止，为付款企业承付货款和银行办理付款、收款的时间，并进行下列操作：
1.从1990年9月15日开始，企业在专业银行开户行要增设“清欠专用存款”和“清欠专用贷款”专户，专业银行在人民银行开户行要增设“清欠专用存款”和“清欠专用贷款”专户。有关专户核算规定如下：
(1)人民银行和专业银行对两个专户，统一使用“××银行往来”和“人民银行往来”会计科目核算，各专业银行对企业在原科目内增设“清欠专用存款”和“清欠专用贷款”两个专户，分别核算各种渠道注入的资金及其形成的存款。
(2)清欠专用贷款发放只能转入清欠专用存款账户，每笔贷款发放，起点和单位均为万元。 (3)专用存款账户资金来源为：发放专用贷款、收回清欠货款、单位结算户转入款(含企业自有存款、财政和企业主管部门拨补资金及专业银行注入的贷款”；专用存款账户资金运用为：承付跨省市清欠款、归还专用贷款。不属于上述范围的款项，人民银行和专业银行均应拒绝办理。
(4)清欠期间，专用贷款暂不定期限。专用存款和贷款，按现行利率于清欠结束时分别计算利息。
2.1990年9月15日至21日这7天为付款企业承付清欠货款的付款期；10月10日前为收款企业收回清欠货款的收款期。各行应按下列程序进行操作：
(1)未在人民银行开户的专业银行基层处所，在承付企业清欠货款时，将企业自有存款清欠的部分从结算户转入清欠专用存款户，需要银行注入的部分同时转入清欠专用存款户，分别使用有关结算凭证和借款凭证，会计分录为：
收：专用资金及贷款 ××企业清欠专用存款户
付：××存款 ××企业结算户
付：××贷款 ××企业流动资金贷款户
(专业银行注入)
付：专用资金及贷款 ××企业清欠专用贷款
(人民银行注入)
将企业承付款通过县辖往来上划管辖行，会计分录为：
收：支行辖内往来 管辖行户
付：专用资金及贷款 ××企业清欠专用存款户
同时销记“清欠定期代收登记薄”。
管辖行收到县辖报单时，办理转账，将款项收进专用资金及贷款 ××处所清欠专用存款户
(2)管辖行本身开户企业承付清欠货款，比照上述基层行处第一个分录办理转账手续。然后连同全辖清欠承付向开户的人民银行办理承付划拨手续，会计分录为：
向人民银行借入清欠专用贷款时：
收：人民银行往来 清欠专用贷款账户
付：人民银行往来 清欠专用存款户
将企业存款及本行注入资金拨入专户存款时：
收：人民银行往来 备用金存款户
付：人民银行往来 清欠专用存款户
通过人民银行联行划拨承付款时：
收：人民银行往来 清欠专用存款户
付：专用资金及贷款 ××处所单位清欠专用存款
(3)人民银行开户行办理专业银行借款、划拨和承付清欠货款时，会计分录为：
向专业银行发放清欠专用贷款时：
收：××银行往来 ××行清欠专用存款户
付：××银行往来 ××行清欠专用贷款户
为专业银行办理自有资金转入时：
收：××银行往来 ××行清欠专用存款户
付：××银行往来 ××储备用金存款户
划拨承付货款时：
收：联行往账
付：××银行往来 ××行清欠专用存款户
同时填发电寄联行报单，向收款●人●银行拍发电报，并在电报摘由中加拍“清欠贷款●字●。
(4)收款方人民银行收到清欠划回的●报并填制电寄补充报单后，一律转入收款企业开户的专业银行清欠专用存款户。会计分录为：
收：××银行往来 ××行清欠专用存款户
付：联行来账
(5)收款企业开户的专业银行收到人民银行送来的清欠托收划回款进账通知后，办理转账，会计分录为：
收：专用资金及贷款 ××单位清欠专用存款户
付：人民银行往来 清欠专用存款户
如收款企业在下属处所开户，应通过县辖往来划转。
处所收到划来清欠托收划回款后，应转入专用资金及贷款 ××单位清欠专用存款户
同时，销记“清欠发出托收登记薄”。
3.为了及时调剂、调度、压缩清欠专用资金和贷款规模，使有限资金能充分发挥更大的清欠效果，在办理清欠收款期内，专业银行对开户企业“清欠专用存款”户内的划回清欠货款，应及时主动归还该企业“清欠专用贷款”户的借款，并相应归还专业银行在人民银行所借清欠专用贷款。人民银行各级行要灵活调度，加强调剂。
五、清欠结束工作
全国范围清理拖欠工作截止期为1990年10月10日。结束工作操作如下：
1.专业银行开户行于10月8日前，转销企业增设的两个专户：
(1)编制“开户企业清欠专户轧算明细表”(附表一)一式三份，一份据以办理转账，二份上报管辖行。
(2)根据明细表将专用存款与专用贷款轧低，会计分录为：
收(或付)专用资金及贷款 专用贷款户
(或专用存款)
付(或收)专用资金及贷款 专用存款户
(或专用贷款)
(3)根据明细表将专用资金轧抵后余额转入一般存款或贷款户。余额为存款时，会计分录为：
收：××存款 ××单位结算户
付：专用资金及贷款 ××单位清欠专用存款户
同时，专业银行开户行可视企业转入结算户存款情况，收回一定比例的一般流动资金贷款。 轧抵后余额为贷款时，采取借新还旧、万元以单位、就高不就低的办法，办理流动资金短期贷款手续，期限最长不得超过半年。
(4)结清两个专户的存、贷款利息。
2.专业银行管辖行(即在人民银行开户的专业银行)根据所属行处“开户企业清欠专户轧算明细表”，汇总编制“全国范围清欠专用资金结算表”(参照附表三)一式四份，随附一份轧算明细表报送开户的人民银行。经人民银行稽核部门稽核后无误并经有关人签章后，二份统计表及明细表留存，二份退回专业银行。
3.专业银行于10月10日转销在人民银行增设的两个专户。
(1)按“企业轧抵后余额”栏数字，调整在人民银行专户的存贷款。在一般情况下，轧抵后存贷款小于原账户余额，将其差额转账，会计分录为：
收：人民银行往来 清欠专用存款户
付：人民银行往来 清欠专用贷款户
(2)按“转入一般存贷户”栏数字向人民银行办理借新还旧手续，并结清两个专户，短期贷款一般不超过半年，结清专用贷款户的会计分录为： 收：人民银行往来 短期贷款户
付：人民银行往来 清欠专用贷款户
付：人民银行往来 备用金存款户
结清专用存款户的会计分录为：
收：人民银行往来 清欠专用存款户
付：人民银行往来 备用金存款户
(3)结清清欠期间人民银行两个专户的存贷款利息。
4.人民银行结清专业银行两个专户手续：
(1)按企业轧抵后，两个专户调整的会计分录为：
收：××银行往来 ××行清欠专用贷款户
付：××银行往来 ××行清欠专用存款户
(2)将专户转入一般存、贷款时的会计分录是：
结清专用贷款户时：
收：××银行往来 ××行清欠专用贷款户
收：××银行往来 ××行备用金存款户
付：××银行往来 ××行短期贷款户
结清专用存款户时：
收：××银行往来 ××行备用金存款户
付：××银行往来 ××行清欠专用存款户
(3)清欠专项贷款已用规模移交专业银行后，未用部分自动注销。
(4)根据各专业银行“全国范围清欠专用资金结算表”汇总编制一式两份，一份留存，一份随附专业银行结算表上报地市分行。地市、省市逐级汇总，经与同级专业银行核对无误后，上报人民银行总行。
(5)结清清欠期间专业银行两个专户的存贷款利息。
5.1990年10月10日全国清欠结束后，仍收到付款企业划回的承付货款时，人民银行转入专业银行备用金存款户，专业银行转入企业结算户。如企业已借入清欠贷款，而划回清欠款较大的，专业银行应收回贷款，人民银行对专业银行的贷款可不作调整。
六、报告制度
除8月30日上报事项，应严格执行外，增报以下二种报表：
1.1990年10月10日清欠结束后，人民银行和专业银行应逐级填报(电传)“全国清欠清欠情况统计表”(附表二)
2.各省、自治区、直辖市及计划单列市清欠办和人民银行，应向国务院清欠办公室和人民银行总行报送全国范围清理拖欠专用资金结算表(附表三)和清欠书面总结。内容包括清欠情况与效果、各方反映、问题和意见。
